JPH0124133B2 - - Google Patents
Info
- Publication number
- JPH0124133B2 JPH0124133B2 JP56032519A JP3251981A JPH0124133B2 JP H0124133 B2 JPH0124133 B2 JP H0124133B2 JP 56032519 A JP56032519 A JP 56032519A JP 3251981 A JP3251981 A JP 3251981A JP H0124133 B2 JPH0124133 B2 JP H0124133B2
- Authority
- JP
- Japan
- Prior art keywords
- sodium nitroprusside
- stabilizer
- sodium
- solution
- adrenochrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 claims description 29
- 229940083618 sodium nitroprusside Drugs 0.000 claims description 29
- 239000003381 stabilizer Substances 0.000 claims description 17
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 12
- RPHLQSHHTJORHI-UHFFFAOYSA-N Adrenochrome Chemical compound O=C1C(=O)C=C2N(C)CC(O)C2=C1 RPHLQSHHTJORHI-UHFFFAOYSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 6
- 229960000304 folic acid Drugs 0.000 claims description 6
- 235000019152 folic acid Nutrition 0.000 claims description 6
- 239000011724 folic acid Substances 0.000 claims description 6
- OHSHFZJLPYLRIP-BMZHGHOISA-M Riboflavin sodium phosphate Chemical compound [Na+].OP(=O)([O-])OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O OHSHFZJLPYLRIP-BMZHGHOISA-M 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 5
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 claims description 5
- 239000011714 flavin adenine dinucleotide Substances 0.000 claims description 5
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 claims description 5
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 claims description 5
- 230000000087 stabilizing effect Effects 0.000 claims description 5
- 102000018832 Cytochromes Human genes 0.000 claims description 4
- 108010052832 Cytochromes Proteins 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims 2
- 239000011782 vitamin Substances 0.000 claims 2
- 229940088594 vitamin Drugs 0.000 claims 2
- 229930003231 vitamin Natural products 0.000 claims 2
- 239000000243 solution Substances 0.000 description 17
- YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 description 12
- 229960002460 nitroprusside Drugs 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 7
- 229940090044 injection Drugs 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 239000003708 ampul Substances 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- VWWQXMAJTJZDQX-UHFFFAOYSA-N [[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [5-(7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10-yl)-2,3,4-trihydroxypentyl] hydrogen phosphate Chemical compound C1=NC2=C(N)N=CN=C2N1C(C(O)C1O)OC1COP(O)(=O)OP(O)(=O)OCC(O)C(O)C(O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000001649 capillary isotachophoresis Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008355 dextrose injection Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940035352 nitroprusside injection Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229950001574 riboflavin phosphate Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3251981A JPS57146714A (en) | 1981-03-09 | 1981-03-09 | Stabilized composition of sodium nitroprusside and its stabilizing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3251981A JPS57146714A (en) | 1981-03-09 | 1981-03-09 | Stabilized composition of sodium nitroprusside and its stabilizing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS57146714A JPS57146714A (en) | 1982-09-10 |
| JPH0124133B2 true JPH0124133B2 (enExample) | 1989-05-10 |
Family
ID=12361206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3251981A Granted JPS57146714A (en) | 1981-03-09 | 1981-03-09 | Stabilized composition of sodium nitroprusside and its stabilizing method |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS57146714A (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3133095B2 (ja) * | 1990-04-25 | 2001-02-05 | 兆岐 史 | 消化器病変組織の硬化剤 |
| JP4604515B2 (ja) * | 2004-03-05 | 2011-01-05 | 大正製薬株式会社 | 眼科用剤 |
| JP4885513B2 (ja) * | 2004-11-01 | 2012-02-29 | ロート製薬株式会社 | オキシメタゾリン含有水性組成物 |
-
1981
- 1981-03-09 JP JP3251981A patent/JPS57146714A/ja active Granted
Non-Patent Citations (1)
| Title |
|---|
| CHEMICAL ABSTRACTS * |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS57146714A (en) | 1982-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1547588B1 (en) | Soft capsule preparation | |
| JP3547755B2 (ja) | オキサリプラティヌムの医薬的に安定な製剤 | |
| JP6879582B2 (ja) | ビオプテリン誘導体を含む固体薬学的組成物およびそのような組成物の使用 | |
| JP6665350B2 (ja) | 注射デバイスのための医薬ヒドロコルチゾン溶液 | |
| HUP0401046A2 (en) | Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan | |
| US4883805A (en) | Stable, Injectable solutions of vinca dimer salts | |
| BG60425B2 (bg) | Инжекционни разтвори,съдържащи антитуморен антрациклинов гликозид | |
| US8258166B2 (en) | Pharmaceutical composition | |
| JPH0124133B2 (enExample) | ||
| WO2023072714A1 (en) | Phytonadione for parenteral administration | |
| RU2219917C2 (ru) | Стабильные растворы митоксантрона | |
| AU2004314154A1 (en) | Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same | |
| CN115518037A (zh) | 一种安全质量稳定的左西孟旦注射剂组合物及其制备方法 | |
| JP2019502751A5 (enExample) | ||
| CN106265492B (zh) | 一种含有帕立骨化醇的药物组合物及其制备方法 | |
| US4915956A (en) | Liquid cisplatin formulations | |
| CN108451901A (zh) | 一种阿扎胞苷的制剂及其制备方法 | |
| KR101487953B1 (ko) | 유기용매 무함유 젬시타빈 수용액 조성물 | |
| Radford et al. | The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump | |
| WO2002017932A1 (fr) | Preparations d'oct | |
| JPS63165322A (ja) | 活性型ビタミンｄ類の経口投与用カプセル剤 | |
| US20070020333A1 (en) | Controlled release of hypnotic agents | |
| WO2019176239A1 (ja) | 容器充填ヒトｐｔｈ（１－３４）液体医薬組成物及びその製造方法 | |
| Matsubayashi et al. | Effects of various storage conditions and alterations of antioxidant contents on chromatic aberration of hydroquinone ointment | |
| Proakis et al. | Blockade of insulin release by certain phenothiazines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |